Nowak Marek, Glowacka Ewa, Kielbik Michal, Kulig Andrzej, Sulowska Zofia, Klink Magdalena
Department of Operating Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Center of Medical Laboratory Diagnostics, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Cytokine. 2017 Jan;89:136-142. doi: 10.1016/j.cyto.2016.01.017. Epub 2016 Feb 8.
Epithelial ovarian cancer is a heterogeneous disease comprising several tumor types that each have multiple histopathological features and different biological behaviors. Recent morphologic and molecular genetic studies have allowed for the categorization of various types of ovarian cancer into two groups: type I and type II. Type I tumors are low-grade and are genetically more stable, while type II tumors are high-grade and genetically unstable. The determination of the type of ovarian cancer may have implications in terms of the appropriate therapeutic strategy because different prognoses and responses to chemotherapeutic agents are observed. Therefore, the current challenge is better recognition of the features of cancer cells, which may result in more individualized therapy. The aim of the current studies was to compare the ability of ovarian cancer cells isolated from tumors, which were classified as type I or type II ovarian cancer, to release pro-inflammatory and immunosuppressive cytokines and heat shock protein (HspA1A). These factors are known to facilitate tumor cell survival, invasion and metastasis. Our studies demonstrated that ovarian cancer cells isolated from patients with type II tumors released high levels of immunosuppressive cytokines (i.e., interleukin 10 and transforming growth factor β) and HspA1A in vitro. Conversely, ovarian cancer cells obtained from of type I tumors were significantly less active. We did not observe any difference in the ability of the isolated cancer cells to secrete pro-inflammatory cytokines, regardless of the type of ovarian cancer. In this study, we found that cancer cells from patients with type II tumors demonstrated more intense activity in regards to survival and metastasis, which should be considered during therapy.
上皮性卵巢癌是一种异质性疾病，由几种肿瘤类型组成，每种肿瘤类型都有多种组织病理学特征和不同的生物学行为。最近的形态学和分子遗传学研究已将各种类型的卵巢癌分为两组：I型和II型。I型肿瘤为低级别肿瘤，基因更稳定，而II型肿瘤为高级别肿瘤，基因不稳定。确定卵巢癌的类型可能对合适的治疗策略有影响，因为观察到不同的预后和对化疗药物的反应。因此，当前的挑战是更好地识别癌细胞的特征，这可能会带来更个体化的治疗。当前研究的目的是比较从被分类为I型或II型卵巢癌的肿瘤中分离出的卵巢癌细胞释放促炎和免疫抑制细胞因子以及热休克蛋白（HspA1A）的能力。已知这些因素有助于肿瘤细胞的存活、侵袭和转移。我们的研究表明，从II型肿瘤患者中分离出的卵巢癌细胞在体外释放高水平的免疫抑制细胞因子（即白细胞介素10和转化生长因子β）和HspA1A。相反，从I型肿瘤中获得的卵巢癌细胞活性明显较低。无论卵巢癌的类型如何，我们未观察到分离出的癌细胞分泌促炎细胞因子的能力有任何差异。在本研究中，我们发现II型肿瘤患者的癌细胞在存活和转移方面表现出更强的活性，在治疗过程中应予以考虑。
